Partying with T1D Guide — Part 4

Cannabis, Ketamine, and Hallucinogens in Type 1 Diabetes

These substances are often described as “not really glucose drugs”. In type 1 diabetes, that framing is misleading. The main risk is loss of reliable self-management: time distortion, altered perception, dissociation, nausea, and unpredictable eating patterns.

Before you read

Make sure you have read Part 1: Partying with T1D to understand the shared principles — the inverted U, set and setting, dose uncertainty, and reduced self-rescue.

This page is not a recommendation or endorsement of using any psychoactive substance. It does not provide instructions for use. It draws from lived experiences of people with type 1 diabetes, focusing on what tends to happen in the body and in glucose patterns, what can go wrong, and what has reduced harm in practice.

The common T1D failure modes

Across lived experience, the most common type 1 diabetes risk patterns with these substances look like this:

  • Unplanned eating (munchies, snacking, “forgot I ate”) — post-event hyperglycaemia if insulin is not given
  • Time distortion — missed boluses, missed hypo treatment, missed set changes
  • Reduced self-rescue — you may recognise a problem but be unable to act cleanly
  • Nausea and vomiting (especially with ketamine and mushrooms) — hypo risk plus dehydration risk
  • Sleep disruption — next-day insulin resistance and care fatigue
  • Alcohol co-use — multiplies risk by adding sedation plus delayed hypoglycaemia

Everything on this page points back to the inverted U (each substance has a narrow manageable zone and a steep drop-off) and dose uncertainty (with unregulated substances, potency can vary and numbers can create false confidence).

The inverted U dose-response curve showing how substance effects progress from no effect through desired effect to confusion, dissociation, and medical emergency

Cannabis (THC) and T1D

The main active compound is THC (tetrahydrocannabinol), which acts primarily via the endocannabinoid system (notably CB1 receptors) and alters perception, attention, mood, appetite, and time sense. Effects vary by product potency, route, and individual sensitivity.

Cannabis is rarely a direct glucose mover. The common risk is behavioural: unannounced eating (“munchies”), time loss, and reduced follow-through on bolusing and hypo treatment.

Typical exposure bands (illustrative, not prescriptive)

Because products vary massively in THC content, dose is best described by route. These ranges exist to make the inverted U concept concrete — not to guide use.

RouteLower exposure bandModerate exposure bandHigher exposure band
Edibles (gummies, brownies, drinks)~2.5–5 mg THC~5–10 mg THC>10–20+ mg THC (often overwhelming with low tolerance)
Inhaled (smoked/vaped)Low exposure (small number of inhalations)Moderate exposureHigh exposure (including concentrates)

Inhaled exposure depends on product potency and inhalation pattern. Moving from “mild” to “too much” can happen quickly, especially when tired, anxious, dehydrated, or drinking.

Onset and duration

  • Onset: inhaled within minutes; edible 30–120 minutes
  • Peak: inhaled 15–45 minutes; edible 1.5–3 hours
  • Total duration: inhaled ~2–4 hours; edible ~4–8+ hours
  • After-effects: sedation, altered sleep, reduced concentration (especially after heavier exposure)

T1D considerations

  • Unplanned eating can cause large post-cannabis highs if insulin is not taken
  • Judgement may be impaired, reducing the chance of bolusing or correcting
  • Closed-loop systems can struggle with repeated unannounced snacks
  • At higher exposure: paranoia, anxiety, panic, and loss of control can make self-care collapse

Ketamine and T1D

Ketamine is a dissociative anaesthetic and primarily an NMDA receptor antagonist. At recreational exposures, it can produce dissociation, altered body ownership, dream-like states, and impaired coordination. In type 1 diabetes, the glucose risk is mostly indirect: dissociation can remove the ability to self-manage even if you know what to do.

Typical exposure bands (illustrative, not prescriptive)

The table below exists to explain why overshooting happens and why “a bit more” can flip the experience into immobility, vomiting, or loss of self-rescue capacity.

RouteLower exposure bandModerate exposure bandHigher exposure band
Nasal (insufflated)~15–30 mg~30–75 mg>75–125+ mg (risk of immobility, vomiting)
Oral~40–75 mg~75–150 mg>150–250+ mg (higher nausea and immobility risk)

Onset and duration

  • Onset: nasal 5–10 minutes; oral 15–30 minutes
  • Peak: 20–60 minutes
  • Total duration: ~45–90 minutes (nasal) to ~1.5–2.5 hours (oral)
  • After-effects: grogginess, impaired balance, confusion; sometimes nausea and vomiting

T1D considerations

  • Not usually a direct glucose-altering substance
  • Biggest risk: loss of ability to self-manage (especially at higher exposure and dissociative states)
  • You may not recognise or treat a hypo while dissociated
  • Alcohol co-use increases the risk of not treating a hypo due to combined sedation and dissociation
  • Ensure at least one person knows you have type 1 diabetes and what severe hypoglycaemia can look like

Hallucinogens — LSD and psilocybin

Classical psychedelics primarily act via serotonin 5-HT2A receptors. They can radically alter perception, emotion, time sense, and the feeling of self. For anyone with type 1 diabetes, the practical risk is that these are long-acting altered states where checking glucose, eating, bolusing, and treating hypos may become unreliable.

LSD (Acid)

LSD is active at microgram exposures, which makes dose uncertainty and product variability a major problem in unregulated contexts.

  • Lower exposure band: ~25–75 µg
  • Moderate exposure band: ~75–150 µg
  • Higher exposure band: >150–300+ µg
  • Onset: 30–90 minutes; Peak: 3–5 hours; Total duration: 8–12 hours (sometimes longer)

Psilocybin (Magic mushrooms)

Psilocybin is converted to psilocin in the body and shares the core psychedelic mechanism. People often describe it as more introspective than LSD, but it can still be intensely dysregulating — especially at higher exposures or in unstable settings. Nausea is commonly reported.

  • Lower exposure band: ~0.5–1.5 g dried
  • Moderate exposure band: ~1.5–3.5 g dried
  • Higher exposure band: >3.5–5+ g dried
  • Onset: 20–60 minutes; Peak: 1.5–3 hours; Total duration: 4–6 hours

Potency varies substantially by species, strain, and preparation — grams can create false certainty.

T1D considerations for psychedelics

  • These can be long-acting altered states: self-care can degrade for hours
  • Checking glucose, eating, bolusing, and treating hypos may become unreliable
  • Time distortion increases the chance of missed insulin failure modes
  • Hypoglycaemia during a trip can be difficult to recognise and treat
  • Set and setting matter more than people expect: anxiety and overstimulation increase risk of panic states

Risk summary

Risk areaT1D-specific concern
Appetite shifts / unplanned eatingLarge highs if insulin is not given; looping snacks can confuse closed loops
Time distortionMissed boluses, missed hypo treatment, missed kit tasks
Dissociation / impaired judgementReduced self-rescue capacity even if you know what to do
Nausea / vomitingHypo risk plus dehydration risk; harder to keep carbs down
Sleep disruptionNext-day insulin resistance, mood vulnerability, care fatigue
Alcohol co-useCombined sedation plus delayed hypoglycaemia risk overnight

Minimum viable harm-reduction plan

This will not make drug use safe, but it can reduce predictable failure modes in type 1 diabetes:

  • Do not go in depleted: eat beforehand, hydrate, and start with a stable glucose trend
  • Keep glucose visible: use CGM alerts where possible and consider sharing CGM data with someone you trust
  • Plan for munchies: assume unplanned eating is likely with cannabis — decide in advance what you will do if you snack (closed-loop users: expect the system to lag behind unannounced eating)
  • Carry hypo treatment you can take under stress: fast carbs that do not require appetite
  • Tell at least one person: someone should know you have type 1 diabetes and what severe hypoglycaemia can look like
  • Avoid stacking variables: mixing substances (especially with alcohol) narrows the margin for error
  • Set and setting are not soft factors: panic states and confusion are common routes into self-care collapse
  • After-effects are real: sleep disruption and emotional sensitivity can linger — expect next-day variability and lower self-care bandwidth
Safety infographic for cannabis, ketamine, and hallucinogens with type 1 diabetes covering preparation, monitoring, harm reduction, and recovery

What this means in practice

  • These substances primarily affect glucose management through behavioural disruption — unplanned eating, time distortion, dissociation, and reduced self-rescue — rather than direct metabolic effects
  • Cannabis munchies are the most common cause of post-use hyperglycaemia when insulin is not given for unplanned snacking
  • Ketamine and psychedelics can create altered states where recognising and treating hypoglycaemia becomes unreliable for hours
  • The inverted U applies to all of these substances: a narrow manageable zone and a steep drop-off into confusion, panic, or immobility
  • The highest-risk pattern is stacking substances plus sleep loss plus missed insulin decisions, not any single drug in isolation

This content is for educational exploration only. It describes average responses and general principles. It is not medical advice and cannot replace individual clinical guidance from your diabetes care team.

Continue the guide

Back to guide overview